The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 39 | — | 20.1x | Near average | |
Growth | 88 | 158.0% | 5.6% | Above average | |
Quality | 46 | -49.7% | 7.6% | Near average | |
Safety | 49 | 0.6x | 0.4x | Near average | |
Capital Return | 25 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Beam Therapeutics Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Beam Therapeutics Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Beam Therapeutics stock witnessed a slight positive revision in the average price target (Consensus) over the past 30 days, rising from 46.14 to 48 dollars, an increase of 4.03%, despite the number of analysts remaining steady at 6. This change reflects a gradual improvement in the individual outlooks of current analysts, indicating cautious optimism despite continued expectations of losses in earnings per share (EPS) for upcoming fiscal periods.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.